Trial Profile
A Study to Compare the Efficacy and Safety of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes (ACS) undergoing Percutaneous Coronary Interventions (PCI)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Mar 2021
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Myocardial infarction; Stroke
- Focus Adverse reactions
- Acronyms PROMETHEUS
- Sponsors Daiichi Sankyo Inc; Eli Lilly and Company
- 02 Nov 2017 Results assessing the association between Stent Diameter and Clinical Outcomes in patients treated with second generation drug eluting stents (n=12527) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 02 Nov 2017 Results assessing the association between stent length and clinical events in patients treated with second generation DES (n=12437) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 30 Aug 2017 Results assessing influence of history of cerebrovascular disease on physicians' treatment choices and clinical outcomes after percutaneous coronary interventions presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology